FOVANE Drug Patent Profile
✉ Email this page to a colleague
When do Fovane patents expire, and when can generic versions of Fovane launch?
Fovane is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in FOVANE is benzthiazide. There is one drug master file entry for this compound. Additional details are available on the benzthiazide profile page.
Summary for FOVANE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 63 |
Patent Applications: | 3,732 |
Formulation / Manufacturing: | see details |
DailyMed Link: | FOVANE at DailyMed |
US Patents and Regulatory Information for FOVANE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | FOVANE | benzthiazide | TABLET;ORAL | 012128-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |